A novel molecule with notable activity against multi-drug resistant tuberculosis

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Computational Biology

Background:

• Multi-drug resistant tuberculosis (MDR-TB) poses a significant global health threat, exacerbated by HIV co-infection.
• Developing new anti-MDR-TB agents with favorable metabolic profiles is a critical scientific challenge.

Purpose of the Study:

• To design and synthesize a novel multifunctional molecule for potential anti-MDR-TB therapy.
• To evaluate the in vitro efficacy, metabolic stability, and safety profile of the designed compound.

Main Methods:

• Computational biology and ligand docking were employed for molecule design.
• A multi-step synthesis was utilized to produce the target compound.
• In vitro assays were performed to assess anti-MDR-TB activity, metabolic stability (CYP/UGT), cytotoxicity, and synergistic effects with PA-824, as well as anti-HIV activity.

Main Results:

• The synthesized compound demonstrated significant in vitro activity against MDR-TB (MIC 1.56μg/mL) with a half-life of 14.4h.
• Favorable metabolic profiles with human cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) isozymes were observed.
• The compound exhibited low cytotoxicity in macrophages and synergistic activity with PA-824, along with in vitro anti-HIV effects.

Conclusions:

• The designed multifunctional molecule shows potential as a therapeutic agent against MDR-TB.
• Its favorable pharmacokinetic and safety profile, combined with synergistic and anti-HIV activities, warrants further investigation.